UNSPSC 51162627: Dimemorfan phosphate

This classification denotes an antitussive agent and anticonvulsant agent with the molecular formula C18H25N.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S203Y5Y1QP, chemically known as 3,17-dimethyl-9-alpha,13-alpha,14-alpha-morphinan phosphate but more generally known as dimemorfan phosphate, which bears US NIH Compound Identifier 5492722. European Medicines Agency schedules Dimemorfan phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01739MIG.

Most nations, for tariff and trade purposes, schedule dimemorfan phosphate under HS 29334990 and SITC 51575. As of Q4 2014, DIMEMORFAN PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCC2C(C1)[C@]34CCCC[C@@H]3[C@H](C2)N(CC4)C.OP(=O)(O)O.

UNSPSC 51162627 Dimemorfan phosphate is a Commodity code that covers pharmaceutical products, though recent state and local solicitations tagged with this code show activity centered on naloxone and over-the-counter pharmaceutical procurement rather than dimemorfan specifically. State and local governments are buying naloxone delivery systems, generic multi-source pharmaceuticals, and OTC products through this code path, sourced via authorized wholesalers and delivered to community health facilities and state-administered programs. Issuing bodies include county health departments (Seminole County, Florida) and multistate cooperative purchasing alliances administering on behalf of participating state and local facilities (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota, Oregon, and other member jurisdictions).

Recent activity spans Florida and the upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2026. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Both procurements require vendors to meet cGMP standards, FDA compliance, and comprehensive insurance coverage. The MMCAP award structure supports sole, dual, or multi-award decisions based on therapeutic considerations and patient safety, with a 3 percent administrative fee on all contract purchases and performance penalties up to $1,500 per violation.